CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity

Abstract

Dendritic cells (DCs) can acquire distinct functional states. To examine how different DC states orchestrate anti-tumor immunity, Koufaki et al. develop mouse models to label and ablate CCR7+ DCs and find that this activation state is essential for tumor control by uniquely priming tumor-specific cytotoxic T lymphocytes (CTLs), sustaining their function and enabling responses to immunotherapy.